Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety
September 21, 2015
A new coformulation of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild) containing tenofovir alafenamide (TAF) -- an improved prodrug of tenofovir -- offered better bone and kidney safety, while maintaining viral suppression, in patients who switched from efavirenz/tenofovir/emtricitabine (Atripla), according to a study presented at ICAAC/ICC 2015 in San Diego.
The study, which was presented by David Shamblaw, M.D., followed 376 individuals living with HIV (median age of 39) who had achieved undetectable viral loads while taking efavirenz/tenofovir/emtricitabine. Of these participants, 251 were switched to elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) and 125 remained on efavirenz/tenofovir/emtricitabine.
After 48 weeks, 96% of the TAF group and 90% of the efavirenz group maintained an undetectable viral load. In terms of bone safety, those in the TAF group had an average change of +1.44% in hip bone mineral density (BMD), compared to -0.24% in the efavirenz group (P < .001). Moreover, the average change in spine BMD was +0.86% for the TAF group and -0.22% for the efavirenz group (P = .048).
In terms of kidney safety, levels of proteinuria and specific proximal tubular proteinuria (indicators of kidney damage) were significantly lower in those in the TAF group than those in the efavirenz group.
Additionally, a second study examined E/C/F/TAF in patients with an estimated glomerular filtration rate (eGFR) between 30-69 mL/min. Glomerular filtration rate is a measure of how well your kidneys filter out waste products, with a number below 60 signifying kidney damage. The study followed 80 patients who had achieved undetectable viral loads, who were then switched to E/C/F/TAF. After 48 weeks, they maintained a stable eGFR and saw significant reduction in levels of proteinuria. These results suggest that E/C/F/TAF could be a safe option for patients who have impaired kidney function.
The U.S. Food and Drug Administration will decide on the new coformulation of E/C/F/TAF by early November 2015.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
This article was provided by TheBodyPRO.com. It is a part of the publication The 55th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.